Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 121
Filter
1.
Transpl Int ; 36: 11729, 2023.
Article in English | MEDLINE | ID: mdl-37841645

ABSTRACT

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.


Subject(s)
Cholangitis, Sclerosing , Inflammatory Bowel Diseases , Liver Transplantation , Humans , Cholangitis, Sclerosing/complications , Cholangitis, Sclerosing/surgery , Risk Factors , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/surgery
3.
Eur Rev Med Pharmacol Sci ; 25(4): 2099-2108, 2021 02.
Article in English | MEDLINE | ID: mdl-33660823

ABSTRACT

OBJECTIVE: Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn's Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics. PATIENTS AND METHODS: 194 CD patients (108 males and 86 females, mean age 48 years (range 38-58 years) were retrospectively reviewed. 147 patients were already treated with anti-TNFα (75.8%), and 47 (24.2%) patients were already treated with anti-TNFα and vedolizumab. Concomitant treatment with steroids was present in 177 (91.2%) patients. RESULTS: At week 12, clinical remission was achieved in 146 (75.2%) patients. After a mean follow-up of 6 months, clinical remission was maintained in 135 (69.6%) patients; at that time, mucosal healing was assessed in 62 (31.9%) patients, and it was achieved in 33 (53.2) patients. Three (1.5%) patients were submitted to surgery. Steroid-free remission was achieved in 115 (59.3%) patients. Both serum C-Reactive Protein and Fecal Calprotectin (FC) levels were significantly reduced with respect to baseline levels during follow-up. A logistic regression, UST therapy as third-line therapy (after both anti-TNFα and vedolizumab), FC >200 µg/g, and HBI ≥8 were significantly associated with lack of remission. Adverse events occurred in 5 (2.6%) patients, and four of them required suspension of treatment. CONCLUSIONS: UST seemed to be really effective and safe in CD patients unresponsive to other biologic treatments, especially when used as second-line treatment.


Subject(s)
Crohn Disease/drug therapy , Ustekinumab/therapeutic use , Adult , Cohort Studies , Female , Humans , Italy , Logistic Models , Male , Middle Aged , Retrospective Studies , Ustekinumab/administration & dosage , Ustekinumab/adverse effects
4.
J Food Sci Technol ; 57(3): 1003-1012, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32123421

ABSTRACT

To meet the needs of new consumers, meat researchers need to develop healthier products. Dietary fibers can be added for structural purposes, to present functional characteristics or to change the composition of the final product. In this study, mixture design was used to investigate the effects of partial substitution of pork fat by inulin, fructooligosaccharides and α-cyclodextrin on the technological and sensory quality characteristics of low-fat Italian type salami. The partial substitution of fat using dietary fibers shows no effect on weight loss, Aw and pH during ripening time. However, the addition of up to 2% α-cyclodextrin increased lightness and reduced redness and yellowness. Up to 2% of inulin or fructooligosaccharides added improved the sensory acceptance, texture parameters and redness. Healthier low-fat Italian type salami can be produced using inulin or fructooligosaccharides as fat substitute for pork fat and still obtain good technological and sensorial results.

5.
Rev. chil. anest ; 49(2): [1-9], 2020.
Article in Spanish | LILACS | ID: biblio-1103170

ABSTRACT

La pandemia de COVID-19 producida por SARS-CoV-2 actualmente en curso anticipa una gran demanda por ventiladores mecánicos (VM), ya que un porcentaje relevante de los contagiados cae rápidamente en insuficiencia respiratoria y requiere de cuidados intensivos. Anticipándose a ese exceso de demanda y considerando que es muy probable que el número actual de ventiladores mecánicos en las unidades de cuidados intensivos (UCI) sean insuficientes, se ha solicitado a la SACH un informe técnico en relación al uso de las máquinas de anestesia como VM.


Subject(s)
Pneumonia, Viral/therapy , Pneumonia, Viral/epidemiology , Ventilators, Mechanical/supply & distribution , Coronavirus Infections/therapy , Coronavirus Infections/epidemiology , Pandemics , Betacoronavirus , Anesthesia/methods , Chile/epidemiology
6.
Rev. chil. anest ; 49(2): [196-202], 2020.
Article in Spanish | LILACS | ID: biblio-1103176

ABSTRACT

En diciembre de 2019, una serie de casos de neumonía de causa desconocida surgieron en Wuhan, Hubei, China, con presentaciones clínicas muy parecidas a la neumonía viral. El análisis de secuenciación profunda de muestras del tracto respiratorio inferior indicó un nuevo coronavirus, que se denominó nuevo coronavirus 2019 (2019-nCoV o SARS-CoV2) [15]. La propagación del virus ha sido extremadamente rápida, tanto así que el 11 de marzo de 2020 y luego de más de 118.000 infectados en 114 países con 4.300 fallecidos a esa fecha, la organización mundial de la salud declaró a la enfermedad COVID-19, causada por 2019-nCoV, como una pandemia.


Subject(s)
Pneumonia, Viral/prevention & control , Hand Disinfection , Coronavirus Infections/diagnosis , Perioperative Care/nursing , Perioperative Period/nursing , Airway Extubation/instrumentation , Betacoronavirus
7.
Chirurg ; 90(7): 542-547, 2019 Jul.
Article in German | MEDLINE | ID: mdl-30848292

ABSTRACT

Posthepatectomy liver failure (PHLF) still represents a severe complication after major liver resection associated with a high mortality. In addition to an insufficient residual liver volume various factors play an important role in the pathophysiology of PHLF. These include the quality of the parenchyma, liver function, perfusion, i.e. maintenance of adequate inflow and outflow, as well as the condition of the patient and comorbidities. While the liver volume is relatively easy to evaluate using modern imaging techniques, the evaluation of liver function and liver quality require a differentiated approach. Both factors can be influenced by the constitutional status of the patient, medical history and previous treatment and must be given sufficient consideration in the risk evaluation. An adequate perfusion, e.g. portal and arterial circulation and adequate outflow by at least one hepatic vein as well an adequate biliary drainage should be always guaranteed in order to allow regeneration of the residual liver tissue. Only the understanding of all these aspects will support the surgeon in a correct and safe evaluation of the resectability. Additionally, the liver surgeon should be aware of all available perioperative and postoperative options to treat and to prevent PHLF. In this review article the most important questions regarding the risk factors related to PHLF are presented and the potential therapeutic and prophylactic management is described. The main goal is to ensure functional operability of the patient if oncological resectability is possible. In other words: in the case of correct oncological indication, the liver surgeon should be able to resect what is resectable or, alternatively, make resectable what primarily was not resectable.


Subject(s)
Liver Failure , Liver Neoplasms , Hepatectomy , Humans , Liver , Liver Function Tests , Liver Neoplasms/surgery , Preoperative Care
8.
Mar Pollut Bull ; 147: 209-218, 2019 Oct.
Article in English | MEDLINE | ID: mdl-29910142

ABSTRACT

Cyst abundance and identity are essential for understanding and predicting blooms, and for assessing the dispersal of toxic target dinoflagellate species by natural or human mediated ways, as with ballast waters. The aim of this study was to apply rapid, specific and sensitive qPCR assays to enumerate toxic dinoflagellate cysts in sediment samples collected from Adriatic harbours. The molecular standard curves of various target species allowed obtaining the rDNA copy number per cyst. The analytical sensitivity for specific standard curves was determined to be 2 or 10 rDNA copies per reaction. The abundance varied in the range of 1-747 dinoflagellate cysts g-1 dry weight. The assays showed greater sensitivity as compared to counts by light microscopy. This qPCR method revealed a powerful tool for the quantification of cysts from toxic dinoflagellate resting stages in sediment samples from Adriatic ports.


Subject(s)
Biological Monitoring/methods , Dinoflagellida/genetics , Harmful Algal Bloom , Real-Time Polymerase Chain Reaction/methods , DNA Copy Number Variations , DNA, Ribosomal/genetics , Dinoflagellida/physiology , Geologic Sediments/microbiology , Mediterranean Sea , Plasmids , Reproducibility of Results , Seasons , Sensitivity and Specificity , Ships
9.
Phys Med ; 32(12): 1712-1716, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27524684

ABSTRACT

INTRODUCTION: Many studies aimed at validating the application of Dual Energy Computed Tomography (DECT) in clinical practice where conventional CT is not exhaustive. An example is given by bone marrow oedema detection, in which DECT based on water/calcium (W/Ca) decomposition was applied. In this paper a new DECT approach, based on water/cortical bone (W/CB) decomposition, was investigated. MATERIALS AND METHODS: Eight patients suffering from marrow oedema were scanned with MRI and DECT. Two-materials density decomposition was performed in ROIs corresponding to normal bone marrow and oedema. These regions were drawn on DECT images using MRI informations. Both W/Ca and W/CB were considered as material basis. Scatter plots of W/Ca and W/CB concentrations were made for each ROI in order to evaluate if oedema could be distinguished from normal bone marrow. Thresholds were defined on the scatter plots in order to produce DECT images where oedema regions were highlighted through color maps. The agreement between these images and MR was scored by two expert radiologists. RESULTS: For all the patients, the best scores were obtained using W/CB density decomposition. CONCLUSIONS: In all cases, DECT color map images based on W/CB decomposition showed better agreement with MR in bone marrow oedema identification with respect to W/Ca decomposition. This result encourages further studies in order to evaluate if DECT based on W/CB decomposition could be an alternative technique to MR, which would be important when short scanning duration is relevant, as in the case of aged or traumatic patients.


Subject(s)
Bone Marrow/diagnostic imaging , Cortical Bone/diagnostic imaging , Cortical Bone/metabolism , Edema/diagnostic imaging , Edema/metabolism , Tomography, X-Ray Computed , Water/metabolism , Adult , Aged , Bone Marrow/metabolism , Feasibility Studies , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged
11.
Chirurgia (Bucur) ; 110(4): 391-5, 2015.
Article in English | MEDLINE | ID: mdl-26305207

ABSTRACT

INTRODUCTION: Synovial sarcomas are rare malignant tumors of soft tissues, arising mainly from periarticular structures. Gastrointestinal localizations are unusual presentation of these rare sarcomas. METHODS: We present the case of a 56- years old man with monophasic synovial sarcoma, arising primarily from the ileum, and causing intussusception. A review of the literature was conducted to gather information about this rare sarcoma. RESULTS: We found that the criteria normally used to determine the prognosis in patients with monophasic synovial sarcoma of soft tissue are poorly applicable for gastrointestinal localizations. CONCLUSIONS: A better characterization of these tumors could identify them as a distinct entity, compared with monophasic synovial sarcomas of soft tissues.


Subject(s)
Ileal Neoplasms/complications , Ileal Neoplasms/surgery , Intussusception/etiology , Intussusception/surgery , Sarcoma, Synovial/complications , Sarcoma, Synovial/surgery , Biomarkers, Tumor/genetics , Humans , Ileal Neoplasms/genetics , Ileal Neoplasms/pathology , Male , Middle Aged , Prognosis , Proto-Oncogene Proteins/genetics , Repressor Proteins/genetics , Sarcoma, Synovial/genetics , Sarcoma, Synovial/pathology , Treatment Outcome
12.
Oncogene ; 34(8): 996-1005, 2015 Feb 19.
Article in English | MEDLINE | ID: mdl-24632610

ABSTRACT

Epithelial-to-mesenchymal transition (EMT) promotes cell motility, which is important for the metastasis of malignant cells, and blocks CD95-mediated apoptotic signaling triggered by immune cells and chemotherapeutic regimens. CD95L, the cognate ligand of CD95, can be cleaved by metalloproteases and released as a soluble molecule (cl-CD95L). Unlike transmembrane CD95L, cl-CD95L does not induce apoptosis but triggers cell motility. Electron paramagnetic resonance was used to show that EMT and cl-CD95L treatment both led to augmentation of plasma membrane fluidity that was instrumental in inducing cell migration. Compaction of the plasma membrane is modulated, among other factors, by the ratio of certain lipids such as sphingolipids in the membrane. An integrative analysis of gene expression in NCI tumor cell lines revealed that expression of ceramide synthase-6 (CerS6) decreased during EMT. Furthermore, pharmacological and genetic approaches established that modulation of CerS6 expression/activity in cancer cells altered the level of C16-ceramide, which in turn influenced plasma membrane fluidity and cell motility. Therefore, this study identifies CerS6 as a novel EMT-regulated gene that has a pivotal role in the regulation of cell migration.


Subject(s)
Cell Membrane/physiology , Cell Movement/genetics , Epithelial-Mesenchymal Transition/genetics , Membrane Fluidity/genetics , Membrane Proteins/genetics , Neoplasms/pathology , Sphingosine N-Acyltransferase/genetics , Cells, Cultured , Down-Regulation , Gene Expression Regulation, Neoplastic , HL-60 Cells , Humans , Jurkat Cells , K562 Cells
14.
Eur Rev Med Pharmacol Sci ; 17(3): 342-8, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23426537

ABSTRACT

BACKGROUND: Colonic diverticulitis shows a high recurrence rate. AIMS: To assess the efficacy of three different therapeutic strategies in preventing diverticulitis recurrence. MATERIALS AND METHODS: One hundred thirty patients suffering from Acute Uncomplicated Diverticulitis (AUD) (81 males, 49 females, mean age 64.71 years, range 40-85) were prospectively assessed. After obtaining remission, considered present when both endoscopic and histological damage were absent, the patients were treated with mesalazine 1.6 g/day (59 patients, group A), or rifaximin 800 mg/day for 7 days every month (52 patients, group B). Clinical, endoscopic and histological follow-up was performed after 6, 12 and thereafter every 12 months after diagnosis of AUD. RESULTS: Seven patients were excluded from final evaluation because they were lost to follow-up. Fifty-five group A patients and 49 group B patients patients were available for the final assessment at the end of a 24-month follow-up. Sustained remission was significantly higher in group A with respect to group B. CONCLUSIONS: Patients taking mesalazine have lower risk of diverticulitis recurrence than patients taking rifaximin because of the lower prevalence of persisting endoscopic and histological inflammation.


Subject(s)
Diverticulitis, Colonic/prevention & control , Gastrointestinal Agents/therapeutic use , Mesalamine/therapeutic use , Rifamycins/therapeutic use , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diverticulitis, Colonic/drug therapy , Diverticulitis, Colonic/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Rifaximin , Secondary Prevention , Time Factors
15.
Arq. bras. med. vet. zootec ; 64(5): 1133-1136, out. 2012. tab
Article in Portuguese | LILACS | ID: lil-655882

ABSTRACT

Relata-se a ocorrência de um surto de brucelose em um rebanho de aproximadamente 1000 animais, livre da doença há 18 anos, certificado pelo Ministério da Agricultura, Pecuária e Abastecimento desde 2006. Dois animais reagiram aos testes sorológicos de diagnóstico por ocasião dos procedimentos de recertificação em 2008. Após o sacrifício deles, Brucella abortus, biovariedade 1, amostra não vacinal, foi isolada e identificada por meio de provas bioquímicas e de biologia molecular (PCR AMOS). A origem do agente no rebanho é de difícil determinação. No entanto, a adoção de procedimentos preconizados pelo Programa Nacional de Controle e Erradicação da Brucelose permitiu evitar a disseminação da enfermidade. Ocorrências como essas, em que rebanhos livres foram infectados após anos sem a ocorrência de brucelose, nunca haviam sido relatadas no Brasil.


A Brucellosis outbreak is reported in a bovine herd free from the disease for over 18 years, officially free since 2006. One heifer and one cow tested positive in serological tests for the 2008 annual recertification in a herd of almost 1000 animals. Isolation and identification by biochemical tests and molecular biology (AMOS PCR) confirmed the infection by a Brucella abortus biovar 1 field strain. It wasn't possible to find the source of the infection. However, adoption of standard procedures prescribed by the Brazilian National Brucellosis and Tuberculosis Control and Eradication Program hindered the spread of the disease. This is the first report of a Brucella infection in an officially Brucellosis-free bovine herd in Brazil.


Subject(s)
Animals , Cattle , Brucella abortus , Brucellosis, Bovine/diagnosis , Brucellosis, Bovine/transmission , Cattle Diseases/diagnosis , Cattle Diseases/transmission , Disease Outbreaks/veterinary
16.
Br J Anaesth ; 107(4): 593-600, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21743068

ABSTRACT

BACKGROUND: The performance of eight currently available paediatric propofol pharmacokinetic models in target-controlled infusions (TCIs) was assessed, in healthy children from 3 to 26 months of age. METHODS: Forty-one, ASA I-II children, aged 3-26 months were studied. After the induction of general anaesthesia with sevoflurane and remifentanil, a propofol bolus dose of 2.5 mg kg(-1) followed by an infusion of 8 mg kg(-1) h(-1) was given. Arterial blood samples were collected at 1, 2, 3, 5, 10, 20, 40, and 60 min post-bolus, at the end of surgery, and at 1, 3, 5, 30, 60, and 120 min after stopping the infusion. Model performance was visually inspected with measured/predicted plots. Median performance error (MDPE) and the median absolute performance error (MDAPE) were calculated to measure bias and accuracy of each model. RESULTS: Performance of the eight models tested differed markedly during the different stages of propofol administration. Most models underestimated propofol concentration 1 min after the bolus dose, suggesting an overestimation of the initial volume of distribution. Six of the eight models tested were within the accepted limits of performance (MDPE<20% and MDAPE<30%). The model derived by Short and colleagues performed best. CONCLUSIONS: Our results suggest that six of the eight models tested perform well in young children. Since most models overestimate the initial volume of distribution, the use for TCI might result in the administration of larger bolus doses than necessary.


Subject(s)
Anesthetics, Intravenous/pharmacokinetics , Propofol/pharmacokinetics , Algorithms , Anesthetics, Intravenous/blood , Calibration , Child, Preschool , Chromatography, High Pressure Liquid , Cleft Lip/surgery , Cleft Palate/surgery , Data Interpretation, Statistical , Female , Humans , Infant , Male , Models, Statistical , Monitoring, Intraoperative , Propofol/blood , Prospective Studies , Reference Values , Reproducibility of Results
17.
Ann Oncol ; 22(5): 1109-1112, 2011 May.
Article in English | MEDLINE | ID: mdl-20924074

ABSTRACT

BACKGROUND: To evaluate the influence of radiotherapy on the selenium serum levels of breast cancer patients. PATIENTS AND METHODS: This prospective study includes 209 breast cancer patients treated by external beam radiotherapy from December 2007 until August 2008. Plasma selenium concentrations were determined before and at the end of the radiotherapeutic treatment. Age, clinical stage, prior chemotherapy, body mass index (BMI) and personal habits (smoking and alcoholism) were recorded for each patient. RESULTS: The mean age was 61 years; the mean BMI was 28.7. One hundred and seventy-four patients (83.3%) were nonsmokers. One hundred and eighty-nine patients (90.4%) showed no drinking habits and 110 (52.6%) have no prior chemotherapy. Sixty patients (28.7%) were in clinical stage I, 141 (67.5%) in clinical stage II and 8 (3.8%) in clinical stage III. At the beginning of radiotherapy, the mean selenium value for all patients was 86.4 µg/l and after radiation this value dropped to 47.8 µg/l. Multivariate analysis showed statistically significant difference in the plasma selenium concentration before and after radiotherapy for age (P > 0.001), BMI (P > 0.001), smoking (P > 0.001), alcoholism (P > 0.001), chemotherapy (P > 0.001) and clinical stage (P > 0.001). CONCLUSIONS: Significant reduction in plasma levels of selenium is recorded in patients undergoing radiotherapy, suggesting attention to the nutritional status of this micronutrient and other antioxidant agents.


Subject(s)
Breast Neoplasms/radiotherapy , Selenium/blood , Antioxidants/metabolism , Female , Humans , Middle Aged , Multivariate Analysis , Nutritional Status , Prospective Studies , Radiotherapy/adverse effects
18.
Br J Anaesth ; 105(4): 448-56, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20710020

ABSTRACT

BACKGROUND: The objective of this study was to develop a pharmacokinetic (PK) model to characterize the influence of obesity on propofol PK parameters. METHODS: Nineteen obese ASA II patients undergoing bariatric surgery were studied. Patients received propofol 2 mg kg(-1) bolus dose followed by a 5-20-40-120 min, 10-8-6-5 mg kg(-1) h(-1) infusion. Arterial blood samples were withdrawn at 1, 3, 5 min after induction, every 10-20 min during propofol infusion, and every 10-30 min for 2 h after stopping the propofol infusion. Arterial samples were processed by high-performance liquid chromatography. Time-concentration data profiles from this study were pooled with data from two other propofol PK studies available at http://www.opentci.org. Population PK modelling was performed using non-linear mixed effects model. RESULTS: The study involved 19 obese adults who contributed 163 observations. The pooled analysis involved 51 patients (weight 93 sd 24 kg, range 44-160 kg; age 46 sd 16 yr, range 25-81 yr; BMI 33 sd 9 kg m(-2), range 16-52 kg m(-2)). A three-compartment model was used to investigate propofol PK. An allometric size model using total body weight (TBW) was superior to all other models investigated (linear TBW, free fat mass, lean body weight, normal fat mass) for all clearance parameters. Variability in V2 and Q2 was reduced by a function showing a decrease in both parameters with age. CONCLUSIONS: We have derived a population PK model using obese and non-obese data to characterize propofol PK over a wide range of body weights. An allometric model using TBW as the size descriptor of volumes and clearances was superior to other size descriptors to characterize propofol PK in obese patients.


Subject(s)
Anesthetics, Intravenous/blood , Models, Biological , Obesity/blood , Propofol/blood , Adult , Aged , Aged, 80 and over , Anesthetics, Intravenous/administration & dosage , Anthropometry , Bariatric Surgery , Body Mass Index , Body Weight , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Obesity/surgery , Propofol/administration & dosage
20.
Eur Rev Med Pharmacol Sci ; 14(1): 47-55, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20184089

ABSTRACT

BACKGROUND AND OBJECTIVES: Our aim was to assess the efficacy and safety of infliximab (IFX) in clinical practice in three Primary Care, Hospital Centers. MATERIAL AND METHODS: From September 2004 to December 2008 62 patients (28 males, 34 females, mean age 30.25 years, range 15-55 years), affected by ulcerative colitis (UC) (23 pts) or by Crohn's disease (CD) (39 patients) were treated. Clinical efficacy, safety, mucosal healing and quality of life were assessed both in UC and CD. RESULTS: A total of 746 infusions were performed. IFX was administered for a mean of 26 months (range 8-44 months). 33/39 (84.61%) pts with CD were in remission under treatment with IFX for a mean time of 19 months (range 12-44 months). Mean Crohn Disease Activity Index (CDAI) score decreased from 295 (range 258-346) to 136 (range 98-136) (p < 0.005). Inflammatory Bowel Disease Quality of Life (IBDQL) improved from 48 (at entry) to 198 (at the end of the study) (p < 0.005). 20/23 (86.95%) patients with UC were in remission under treatment with IFX for a mean of 18 months (range 8-34 months). Mean Disease Activity Index (DAI) decreased from 11 (range 9-12) to < 3 (range 2-3) (p < 0.05). Mean Mayo Subscore for Endoscopy decreased from 3 to < 1 (range 0-1). IBDQL improved from 56 (at entry) to 194 (at the end of the study) (p < 0.005). Only 5 patients (8.06%) experienced side-effects. CONCLUSIONS: Long-term outpatients treatment with IFX seems to be safe and effective in managing patients affected by IBD in clinical practice.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Gastrointestinal Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Adolescent , Adult , Ambulatory Care , Anti-Inflammatory Agents/adverse effects , Antibodies, Monoclonal/adverse effects , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/pathology , Crohn Disease/drug therapy , Crohn Disease/pathology , Female , Gastrointestinal Agents/adverse effects , Humans , Infliximab , Male , Middle Aged , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...